- Introduced
- In committee
- Passed the House
- Passed the Senate
- LawPub. L. 119-138
What it changed
About this text
Text: Enrolled The final text both chambers passed, sent to the President to sign. If signed, it becomes law.
4 other versions
- Enrolled The final text both chambers passed, sent to the President to sign. If signed, it becomes law.
- Placed on calendar The text put on a chamber's list of bills that may be brought up for a vote.
- Engrossed The official text as one chamber (House or Senate) passed it.
- Reported The text a committee sent back to its chamber, often with changes, recommending a vote.
- Introduced The text as a member of Congress first filed it. Most bills never get further than this.
This law changed existing law, but we couldn't automatically match its changes to the Code.
Its own words follow, each change we couldn't place marked where it stands.
9 changes we couldn't place in the Code
- accelerating access to critical therapies for als act § 7 In the bill’s text
- accelerating access to critical therapies for als act § 2(f) In the bill’s text
- accelerating access to critical therapies for als act § 2(b) In the bill’s text
- accelerating access to critical therapies for als act § 2(c) In the bill’s text
- accelerating access to critical therapies for als act § 2(c) In the bill’s text
- accelerating access to critical therapies for als act § 2(c) In the bill’s text
- accelerating access to critical therapies for als act § 2(e) In the bill’s text
- accelerating access to critical therapies for als act § 4 In the bill’s text
- accelerating access to critical therapies for als act § 4 In the bill’s text
Sec. 1. SHORT TITLE. This Act may be cited as the “Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026”.
Sec. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT.
(a) In General.— Section 7 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended by striking “2026” and inserting “2031”.
This change is to a law outside the US Code: the bill cites it only by Public Law number.
(b) Grants for ALS Research.— Section 2(f) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by striking “2026” and inserting “2031”.
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
Sec. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON THERAPIES FOR ALS.
(a) Renewal of Grants for Research on Therapies for ALS Review.— Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following:
(4) Renewal of grants for research on therapies for als review.— In reviewing applications for renewals of a grant awarded under this section with respect to an investigational drug, the Secretary shall request from the manufacturer or sponsor, and assess, the enrollment, safety, and any available efficacy data relating to the investigational drug in the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis.
.
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
(b) Reporting Safety Data.— Section 2(c) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended—
(1) in paragraph (2)(B), by striking “and” at the end;
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
(2) in paragraph (3), by striking the period at the end and inserting “; and”; and
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
(3) by adding at the end the following:
(4) the entity seeking such grant will promptly report any new and serious adverse events and safety information that is considered to be unexpected with respect to the phase 3 trial to the grant-making institution, in addition to complying with the safety reporting requirements under section 312.32 of title 21, Code of Federal Regulations (or any successor regulations).
.
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
(c) Clarifying Participating Clinical Trial Definition.— Section 2(e) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following:
(4) The term “phase 3”, with respect to a clinical trial, includes a phase 2/3 combined trial that begins enrollment within a timeframe, determined by the Secretary through the terms and conditions of the grant awarded under this section.
.
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
Sec. 4. FDA RARE NEURODEGENERATIVE DISEASE ACTION PLAN. Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360aa note) is amended—
(1) in the section heading, by striking “als and other rare neurodegenerative disease action plan” and inserting “fda rare neurodegenerative disease action plan”; and
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.
(2) by adding at the end the following:
(c) FDA Rare Neurodegenerative Disease Action Plan.—
(1) In general.— Not later than 18 months after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration an action plan that includes a description of the actions that the Food and Drug Administration intends to take during the 5-year period following publication of the action plan with respect to the program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives described in subsection (a).
(2) Report.— Not later than 5 years after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration a report that describes the actions taken by the Food and Drug Administration under the action plan published under paragraph (1) and the extent to which such action plan meets the requirements specified in paragraph (1).
.
We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.